Other cardiovascular drugs × cardiovascular events

TrialNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2025

Canagliflozin and iron metabolism in the CREDENCE trial.

Akihiko Koshino et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 4,401 people · 2025

Randomised comparison

Reduced cardiovascular events

−30%−44% to −13%

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.70, 95% CI 0.56–0.87

One number in the abstract

the abstract, start to end

disease or kidney failure (hazard ratio 0.70, 95% CI 0.56, 0.87) was

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.700.56–0.87
SGLT2 inhibitorsOther cardiovascular drugsCardiovascular events
1 / 3

2 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 39304530